Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib

Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kermiche-Rahali, Sabrina, Di Fiore, Aude, Drieux, Fanny, Di Fiore, Frédéric, François, Arnaud, Scotté, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735470/
https://www.ncbi.nlm.nih.gov/pubmed/23914915
http://dx.doi.org/10.1186/1477-7819-11-171
Descripción
Sumario:Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.

Ejemplares similares